PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 97.6% from PeptideMeter with 95.2% from the supplier?

Asked 20 Aug 2024Modified 21 months agoViewed 24k times
30

For reference: 97.6% · PeptideMeter · 95.2%.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What would you check first, and what would you conclude from each outcome?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
MS
askedmira_sundqvist19k1820 Aug 2024
7Related: the same reasoning applies to the counter-ion question. – Dr_Malik_Osei 27 days ago
add a comment

5 Answers

Sorted by votes
26

The method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

More usefully, sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DS
answeredDr_Hanne_Solberg40k3819 Sept 2024
2Small correction: the units in the third paragraph should be micrograms, not milligrams. – Dr_Idris_Coulibaly 8 months ago
Do you have a reference for the last claim? Not disputing it, just want to read it. – Dr_Ilse_Vandenberg 6 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
17

Start from what the detector sees, because that tells you what the number means.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
VI
answeredvialroom87k1487 Sept 2024
5The arithmetic checks out. I ran the same numbers and got the same result. – vialroom 30 days ago
add a comment
15

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
TN
answeredtabular_nums47k3827 Aug 2024
8This is the answer I was looking for three months ago. – lyoph_cake 8 months ago
7The arithmetic checks out. I ran the same numbers and got the same result. – rota_site 6 months ago
add a comment
11

More usefully, area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
DB
answeredDr_Fatima_Belkacem52k13813 Nov 2024
7Worth flagging that this changed in 2025, so older answers on the site are out of date. – Dr_Ravi_Selvarajah 5 months ago
add a comment
-1

It helps to be literal here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Compare purity within a single laboratory on the same method, never across laboratories.

edited 22 Oct 2024 by tare_and_weigh — reworded for clarity after a comment

shareimprove this answerflag
TW
answeredtare_and_weigh18k2830 Sept 2024

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.